Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty

Atherosclerosis

Volumn 232, Issue 1, 2014, Pages 119-124

  Gremmel, Thomas ^a   Xhelili, Endri ^a   Steiner, Sabine ^a   Koppensteiner, Renate ^a   Kopp, Christoph W ^a   Panzer, Simon ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angioplasty; Coronary artery disease; Peripheral arterial disease; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; ENOXAPARIN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; MONOCYTE PLATELET AGGREGATE; PADGEM PROTEIN; PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; MULTIPLE ELECTRODE AGGREGOMETRY; PERIPHERAL ARTERY STENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET AGGREGATION ASSAY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY; CORONARY ARTERY DISEASE; PERIPHERAL ARTERIAL DISEASE; PLATELET REACTIVITY;

ADENOSINE DIPHOSPHATE; AGED; ANGIOPLASTY; ANGIOPLASTY, BALLOON, CORONARY; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; P-SELECTIN; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL ARTERIAL DISEASE; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; STENTS; TICLOPIDINE;

EID: 84891615644     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.10.027     Document Type: Article

References (36)

1. van Kuijk J.P., Flu W.J., Welten G.M., et al. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur Heart J 2010, 31:992-999.
2. Sukhija R., Aronow W.S., Yalamanchili K., Sinha N., Babu S. Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. Am J Cardiol 2004, 94:1358-1359.
3. Dieter R.S., Tomasson J., Gudjonsson T., et al. Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vasc Med 2003, 8:233-236.
4. Welten G.M., Schouten O., Hoeks S.E., et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. JAm Coll Cardiol 2008, 51:1588-1596.
5. McDermott M.M., Mehta S., Ahn H., Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. JGen Intern Med 1997, 12:209-215.
6. Davi G., Patrono C. Platelet activation and atherothrombosis. NEngl J Med 2007, 357:2482-2494.
7. Spiliopoulos S., Pastromas G., Katsanos K., Kitrou P., Karnabatidis D., Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. JAm Coll Cardiol 2013, 61:2428-2434.
8. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
9. Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. JAm Coll Cardiol 2009, 53:849-856.
10. Yano Y., Ohmori T., Hoshide S., et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Eur Heart J 2008, 29:1729-1738.
11. Badr Eslam R., Lang I.M., Koppensteiner R., Calatzis A., Panzer S., Gremmel T. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol 2012 Oct 2, [E-pub ahead of print]. 10.1016/j.ijcard.2012.09.103.
12. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009, 101:333-339.
13. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W. Ahigh maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. Int J Cardiol 2012, 160:109-113.
14. Eslam R.B., Reiter N., Kaider A., Eichinger S., Lang I.M., Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J 2009, 30:1831-1836.
15. Vandendries E.R., Furie B.C., Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004, 92:459-466.
16. Wagner D.D. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005, 25:1321-1324.
17. Shattil S.J., Cunningham M., Hoxie J.A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987, 70:307-315.
18. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of invivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001, 104:1533-1537.
19. Furman M.I., Barnard M.R., Krueger L.A., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. JAm Coll Cardiol 2001, 38:1002-1006.
20. Furman M.I., Benoit S.E., Barnard M.R., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. JAm Coll Cardiol 1998, 31:352-358.
21. Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. JAm Coll Cardiol 2010, 56:919-933.
22. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. JClin Invest 1999, 103:879-887.
23. Leger A.J., Covic L., Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006, 114:1070-1077.
24. Dormann D., Clemetson K.J., Kehrel B.E. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000, 96:2469-2478.
25. Soslau G., Class R., Morgan D.A., et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. JBiol Chem 2001, 276:21173-21183.
26. Adam F., Guillin M.C., Jandrot-Perrus M. Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. Eur J Biochem 2003, 270:2959-2970.
27. Kim S., Foster C., Lecchi A., et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002, 99:3629-3636.
28. Tricoci P., Huang Z., Held C., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. NEngl J Med 2012, 366:20-33. TRACER Investigators.
29. Morrow D.A., Braunwald E., Bonaca M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. NEngl J Med 2012, 366:1404-1413. TRA 2P-TIMI 50 Steering Committee and Investigators.
30. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med 2012, 366:9-19. ATLAS ACS 2-TIMI 51 Investigators.
31. Becker R.C., Moliterno D.J., Jennings L.K., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373:919-928. TRA-PCI Investigators.
32. Bonaca M.P., Scirica B.M., Creager M.A., et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013, 127:1522-1529.
33. Bobbert P., Stellbaum C., Steffens D., et al. Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy. Blood Coagul Fibrinolysis 2012, 23:723-728.
34. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. JAm Coll Cardiol 2006, 47:27-33.
35. Estes J.W. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980, 5:204-220.
36. Collignon F., Frydman A., Caplain H., et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995, 73:630-640.